[8-K] CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Reports Material Event

Rhea-AI Filing Summary

Charles River Laboratories International, Inc. (CRL) announced the conclusion of an SEC investigation without an enforcement recommendation. The SEC’s Division of Enforcement informed the company that, based on the information available to it, it does not intend to recommend an enforcement action related to the company’s sourcing of non-human primates and related disclosures. The company’s Audit Committee also completed its own independent investigation into the same matters, reporting no material findings. This removes a regulatory overhang that had been disclosed since May 2023.

Positive

• SEC investigation concluded with no enforcement recommendation, eliminating a significant regulatory overhang related to sourcing of non-human primates and associated disclosures.
• Audit Committee’s independent investigation ended with no material findings, supporting the company’s prior disclosures on the issues reviewed.

Negative

• None.

Insights

Regulatory and legal risk analyst

SEC ends probe into CRL with no enforcement action, easing legal overhang.

The key development is that the SEC’s Division of Enforcement has concluded its investigation into Charles River Laboratories regarding the sourcing of non-human primates and related disclosures, and stated it does not intend to recommend an enforcement action. This directly addresses a regulatory risk first disclosed in May 2023.

In parallel, the company’s Audit Committee completed an independent investigation into the same issues and reported no material findings. While this does not provide additional financial data, it clarifies that internal reviewers did not identify issues requiring material disclosure changes tied to these matters.

For investors focused on compliance and reputational risk, the resolution of both the SEC inquiry and the internal review reduces uncertainty around this topic. Future disclosures in periodic reports can now focus more on operating and financial performance rather than this specific investigation.

0001100682false00011006822025-11-142025-11-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

November 14, 2025

Date of Report (Date of earliest event reported)

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware			001-15943			06-1397316
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

251 Ballardvale Street

Wilmington, Massachusetts 01887

(Address of Principal Executive Offices) (Zip Code)

781-222-6000

(Registrant’s Telephone Number, including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $0.01 par value			CRL			New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

As previously disclosed, on May 16, 2023, Charles River Laboratories International, Inc., (Company) received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena and additional inquiries, primarily related to the sourcing of non-human primates and related disclosures. In addition, the Company’s Audit Committee retained counsel to conduct an independent investigation into certain issues raised in the investigation.

On November 14, 2025, the SEC’s Division of Enforcement (Division) notified the Company that it concluded its investigation and, based on the information available to the Division, it does not intend to recommend an enforcement action by the SEC against the Company. Similarly, the Company’s independent investigation into these matters has also concluded, with no material findings.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Date:			November 17, 2025			By:			/s/ Matthew L. Daniel
									Matthew L. Daniel, Corporate Senior Vice President,
									General Counsel, Corporate Secretary & Chief Compliance Officer

3

FAQ

What did Charles River Laboratories (CRL) announce in this 8-K filing?

Charles River Laboratories reported that the SEC’s Division of Enforcement has concluded its investigation into the company and, based on the information available to it, does not intend to recommend an enforcement action. The company’s Audit Committee also completed an independent investigation with no material findings.

What was the SEC investigation into CRL about?

The investigation related primarily to Charles River Laboratories’ sourcing of non-human primates and related disclosures. The SEC requested information beginning in May 2023, including a document subpoena and additional inquiries.

Did the SEC take any enforcement action against Charles River Laboratories?

No. The SEC’s Division of Enforcement notified Charles River Laboratories that it concluded its investigation and, based on the information available to it, does not intend to recommend an enforcement action against the company.

What were the results of Charles River Laboratories’ internal investigation?

The Audit Committee of Charles River Laboratories’ Board retained counsel to conduct an independent investigation into issues raised in the SEC investigation. That internal investigation has concluded with no material findings.

How long had the SEC investigation into CRL been ongoing?

Charles River Laboratories first disclosed receiving an SEC Enforcement Division inquiry on May 16, 2023. The SEC later expanded this into a document subpoena and additional inquiries before concluding the investigation on November 14, 2025.

Does this 8-K include any new financial results for Charles River Laboratories (CRL)?

No. This report focuses on the conclusion of the SEC and internal investigations related to sourcing of non-human primates and related disclosures; it does not provide new financial or earnings information.